MDM2 and cancer: Not only direct STAT3 or p53 target molecules, but also factors (HSP90, MDM2) or pathways (such as the mevalonate pathway) involved in this feedback loop could be exploited to regulate both STAT3 and p53-mediated signaling for cancer therapies.